Study of immunotherapy plus targeted drug for adrenal cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether combining camrelizumab (an immune treatment) with apatinib (a targeted drug) can shrink recurrent or metastatic adrenal cancer after standard treatment didn’t work. It may help some people control tumor growth when other treatments have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have adrenal cortical carcinoma confirmed by pathology (a lab test on tissue).
- Your cancer has come back, spread, or can’t be removed, and it has worsened after first-line treatment.
- You are 18 years or older, and your daily functioning is fairly good (ECOG 0–1).
- A scan shows at least one measurable tumor spot that can be followed on treatment.
- Your blood counts and organ function (liver, kidneys, and heart-related labs) are within required limits before starting.
- You can use effective birth control during treatment and for 120 days after the last dose, and you agree by signing consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Hear when a new Adrenocortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.